PUBLISHER: DelveInsight | PRODUCT CODE: 1147338
PUBLISHER: DelveInsight | PRODUCT CODE: 1147338
DelveInsight's "Genital Herpes- Market Insight, Epidemiology and Market Forecast-2032" report delivers an in-depth understanding of Genital Herpes, historical and forecasted epidemiology as well as the Genital Herpes trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan and China.
The Genital Herpes market report provides emerging drugs, Genital Herpes market share of the individual cancer types, current and forecasted Genital Herpes market size from 2019 to 2032 segmented by eight major markets. The Report also covers current Genital Herpes unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.
Study Period: 2019-2032.
The DelveInsight's Genital Herpes epidemiology report gives a thorough understanding of Genital Herpes by including details such as overview of Genital Herpes, advantages, disadvantages and available therapies. Comprehensive epidemiology insight of Genital Herpes. It is a chronic sexually transmitted infection (STI) characterized by recurrent, self-limited genital ulcers caused by herpes simplex virus type 1 (HSV-1) or type 2 (HSV-2). It can cause blisters and open sores (lesions) in the genital area, but it can also be asymptomatic, meaning a person does not show symptoms.
Genital herpes can be asymptomatic or have mild symptoms that go unrecognized. When symptoms occur, genital herpes is characterized by one or more genital or anal blisters or ulcers. Additionally, symptoms of a new infection often include fever, body aches, and swollen lymph nodes. After an initial episode, which can be severe, symptoms may recur. Genital herpes caused by HSV-1 typically does not recur frequently. With HSV-2, recurrent symptoms are common; however, recurrences are often less severe than the first episode and tend to decrease over time.
Currently, there is no cure for genital herpes. Treatment with prescription antiviral medications may help sores heal sooner during an initial outbreak, lessen the severity and duration of symptoms in recurrent outbreaks, reduce the frequency of recurrence, and minimize the chance of transmitting the herpes virus to another. Antiviral medications used for genital herpes include acyclovir, valacyclovir, and famciclovir. These drugs can be used for episodic treatment or long-term suppressive therapy
The epidemiology section provides the insights about historical and current patient pool and forecasted trend for each eight major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted Genital Herpes epidemiology scenario in the 8MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), Japan, and China from 2019 to 2032.
In 2021, the total diagnosed Genital Herpes cases per year were 1.6 million in the 8MM which are expected to grow during the study period, i.e., 2019-2032.
The disease epidemiology covered in the report provides historical as well as forecasted Genital Herpes epidemiology [segmented as Prevalent HSV infected cases, Symptomatic Genital Herpes cases per year, Gender-specific cases of Genital Herpes, Diagnosed Genital Herpes cases per year, Total recurrent cases of Genital Herpes, and Treated patient pool of Genital Herpes] in the 8MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan and China from 2019 to 2032.
The epidemiology segment also provides the Genital Herpes epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China.
The drug chapter segment of the Genital Herpes report encloses the detailed analysis of Genital Herpes marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also helps to understand the Genital Herpes clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The report provides the details of the emerging therapies under the late and mid-stage of development for Genital Herpes treatment.
The Genital Herpes market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Genital Herpes market trends by analyzing the impact of current therapies on the market, unmet needs, and demand of better technology.
This segment gives a thorough detail of Genital Herpes market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Genital Herpes in 8MM is expected to witness a major change in the study period 2019-2032.
The Genital Herpes market size in the 8MM is expected to change during the study period 2019-2032. The Genital Herpes therapeutic market in the eight major markets is expected to increase during the study period (2019-2032). In 2021, the total market size of Genital Herpes was approximately USD 1,125 million which is expected to rise during the study period (2019-2032).
The total market size of Genital Herpes in the United States accounted for USD 417 million in 2021 which is expected to rise during the study period (2019-2032).
In EU5, the total market size of Genital Herpes was USD 342 million in 2021, which is expected to rise during the study period (2019-2032).
In Japan, the total market size of Genital Herpes was USD 69 million in 2021, which is expected to rise during the study period (2019-2032).
In China, the total market size of Genital Herpes was USD 296 million in 2021, which is expected to rise during the study period (2019-2032).
This section focuses on the rate of uptake of the potential drugs recently launched in the Genital Herpes market or expected to get launched in the market during the study period 2019-2032. The analysis covers Genital Herpes market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses key players involved in developing Genital Herpes.
The report covers the detailed information of collaborations, acquisition, and merger, licensing patent details, and other information for emerging Genital Herpes.
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
To keep up with current market trends, we take KOLs and SMEs ' opinions working in the Genital Herpes domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Genital Herpes market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
We perform Competitively and Market Intelligence analysis of the Genital Herpes Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.